Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 21 (6), 26

Lipoic Acid and Other Antioxidants as Therapies for Multiple Sclerosis

Affiliations
Review

Lipoic Acid and Other Antioxidants as Therapies for Multiple Sclerosis

Carin Waslo et al. Curr Treat Options Neurol.

Abstract

Oxidative stress (OS), when oxidative forces outweigh endogenous and nutritional antioxidant defenses, contributes to the pathophysiology of multiple sclerosis (MS). Evidence of OS is found during acute relapses, in active inflammatory lesions, and in chronic, longstanding plaques. OS results in both ongoing inflammation and neurodegeneration. Antioxidant therapies are a rational strategy for people with MS with all phenotypes and disease durations. PURPOSE OF REVIEW: To understand the function of OS in health and disease, to examine the contributions of OS to MS pathophysiology, and to review current evidence for the effects of selected antioxidant therapies in people with MS (PwMS) with a focus on lipoic acid (LA). RECENT FINDINGS: Studies of antioxidant interventions in both animal and in vivo models result in reductions in serum markers of OS and increases in levels and activity of antioxidant enzymes. Antioxidant trials in PwMS, while generally underpowered, detect short-term improvements in markers of OS and antioxidant defenses, and to a lesser extent, in clinical symptoms (fatigue, depression). The best evidence to date is a 2-year trial of LA in secondary progressive MS which demonstrated a significant reduction of whole-brain atrophy and trend toward improvement in walking speed. Antioxidant therapy is a promising approach to treat MS across the spectrum and duration of disease. Rigorous and well-powered trials are needed to determine their therapeutic benefits.

Keywords: Antioxidant; Lipoic acid; Multiple sclerosis; Neurodegeneration; Neurological disease; Neurology.

Similar articles

See all similar articles

Cited by 2 articles

References

    1. Neurology. 2000 Feb 8;54(3):552-7 - PubMed
    1. FASEB J. 2000 Apr;14(5):691-8 - PubMed
    1. Complement Ther Med. 2000 Jun;8(2):97-105 - PubMed
    1. Biochim Biophys Acta. 2000 Nov 20;1460(2-3):268-75 - PubMed
    1. Drug Metab Dispos. 2001 Jun;29(6):855-62 - PubMed

LinkOut - more resources

Feedback